Roche’s Acquisition of TIB Molbiol Group

Roche's Acquisition of TIB Molbiol Group

Gleiss Lutz advised Roche on the deal. Hengeler Mueller advised the shareholders of TIB Mobil Group on the transaction.

The global pharmaceutical and diagnostics group Roche announced its acquisition of all shares in the Berlin-based TIB Molbiol Group, an expert in molecular diagnostics. The transaction is subject to the customary conditions and is expected to close in the fourth quarter of 2021.

The acquisition will expand Roche’s broad portfolio in molecular diagnostic solutions with a wide range of assays for infectious diseases, such as SARS-CoV-2 variants.

Roche is a global company specialising in the research and development of medicines and diagnostics. It is also the world’s largest biotech company with medicines for oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Founded in 1896 and headquartered in Basel, Switzerland, the Roche Group operates in over 100 countries and employs approximately 100,000 people worldwide in 2020. In 2020, Roche invested CHF 12.2 billion in research and development and achieved sales of CHF 58.3 billion. 

The biotechnology company TIB Molbiol was founded in 1990 and has been supplying the international market with diagnostic and research reagents ever since. As a manufacturer of customised oligonucleotides, the company is a partner in the development of molecular diagnostics and has a broad portfolio of diagnostic assays. The company, with registered office in Berlin, has locations in the U.S., Colombia, Italy, Spain and Australia.

Dr Ruben Perren und Dr Felix Kobel from Roche’s legal department acted as lead counsel on the transaction.

The Gleiss Lutz team included Dr Alexander Schwarz (Picture – partner, Düsseldorf), Dr Martin Viciano Gofferje (partner, Berlin, both lead), Dr Fabian Mumme (Düsseldorf), Dr Christoph Meissner (Berlin), Friedrich Baumgärtel, Kai Zimutta (both Düsseldorf, all M&A), Dr Alexander Molle (partner), Jan Hinrichs, Dr Felix Müller (all IP/IT), Dr Enno Burk (counsel, Healthcare, all Berlin), Dr Johann Wagner (partner, Tax, Hamburg), Dr Jacob von Andreae (partner), Aylin Hoffs, Matthias Hahn, Lennart Förster (all Public Business Law, Düsseldorf), Dr Ingo Brinker (partner), Dr Iris Benedikt-Buckenleib (counsel, both Competition/Antitrust, Munich), Dr Stefan Lingemann (partner), Josefine Chakrabarti (both Berlin), Dr Simona Kreis (Hamburg, all Employment), Konrad Discher (counsel, Real Estate, Frankfurt).

The Hengeler Mueller was led by partner Kai-Steffen Scholz (M&A/Corporate) and included partners Wolfgang Spoerr, Jan Bonhage (both Regulatory) (all Berlin), Markus Ernst (Tax, Munich), Hendrik Bockenheimer (Employment, Frankfurt) and Christoph Stadler (Antitrust, Düsseldorf), counsel Alexander Bekier, Marvin Vesper-Gräske (both M&A/Corporate), Matthias Berberich (IP/IT) (all Berlin) as well as associates Niclas Bettien (M&A/Corporate, Berlin), Michael Schramm (Düsseldorf), Wiebke Lemmer, Anton O. Petrov (both Berlin) (all Regulatory), Tim Würstlin (Tax, Munich), Selina Rohr (Employment, Frankfurt), Cornelia Gersch (IP/IT, Berlin) and Christian Dankerl (Antitrust, Düsseldorf).

Involved fees earner: Friedrich Baumgärtel – Gleiss Lutz; Iris Benedikt-Buckenleib – Gleiss Lutz; Ingo Brinker – Gleiss Lutz; Josefine Chakrabarti – Gleiss Lutz; Konrad Discher – Gleiss Lutz; Lennart Förster – Gleiss Lutz; Matthias Hahn – Gleiss Lutz; Jan Hinrichs – Gleiss Lutz; Aylin Hoffs – Gleiss Lutz; Simona Kreis – Gleiss Lutz; Stefan Lingemann – Gleiss Lutz; Christoph Meissner – Gleiss Lutz; Alexander Molle – Gleiss Lutz; Felix Müller – Gleiss Lutz; Fabian Mumme – Gleiss Lutz; Alexander Schwarz – Gleiss Lutz; Martin Viciano Gofferje – Gleiss Lutz; Jacob von Andreae – Gleiss Lutz; Johann Wagner – Gleiss Lutz; Kai Zimutta – Gleiss Lutz; Alexander Bekier – Hengeler Mueller; Matthias Berberich – Hengeler Mueller; Niclas Bettien – Hengeler Mueller; Hendrik Bockenheimer – Hengeler Mueller; Jan Bonhage – Hengeler Mueller; Christian Dankerl – Hengeler Mueller; Markus Ernst – Hengeler Mueller; Cornelia Gersch – Hengeler Mueller; Wiebke Lemmer – Hengeler Mueller; Anton Petrov – Hengeler Mueller; Selina Rohr – Hengeler Mueller; Kai-Steffen Scholz – Hengeler Mueller; Michael Schramm – Hengeler Mueller; Wolfgang Spoerr – Hengeler Mueller; Christoph Stadler – Hengeler Mueller; Marvin Vesper-Gräske – Hengeler Mueller; Tim Würstlin – Hengeler Mueller;

Law Firms: Gleiss Lutz; Hengeler Mueller;

Clients: Roche; TIB Molbiol Syntheselabor GmbH;

Federica Tiefenthaler

Author: Federica Tiefenthaler